Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$12.47M-41.5%$14.76M-38.0%$16.05M-42.9%$19.95M-32.9%$21.32M-34.6%
-$128.58M+80.5%-$546.38M-75.0%-$506.01M-28.3%-$528.73M-32.1%-$660.12M-122%
-$119.15M+71.6%-$171.43M+60.4%-$277.32M+24.5%-$294.95M+25.0%-$419.27M-40.8%
-$133.28M+83.8%-$553.86M-16.8%-$665.69M-62.8%-$690.89M-61.7%-$821.89M-153%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Pacific Biosciences of California's revenue?
Pacific Biosciences of California (PACB) generated $160.0M in revenue over the trailing twelve months, up 5.0% year over year.
Is Pacific Biosciences of California profitable?
Pacific Biosciences of California is not currently profitable: it reported a net loss of $128.6M over the trailing twelve months, a -80.3% net margin.
What are Pacific Biosciences of California's profit margins?
Gross margin is 37.5% and operating margin is -83.3%, with a -80.3% net margin.
What is Pacific Biosciences of California's earnings per share?
Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
Where does Pacific Biosciences of California's income statement data come from?
Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.